CompanyDrug

GenSci161 Wins NMPA Clinical Trial Acceptance for CTD-ILD, Expanding Bispecific Antibody Pipeline of Changchun High & New Technology

Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal
CompanyDeals

Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

CompanyPolicy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer's Disease in the United States
CompanyDrug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

CompanyDrug

Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent
CompanyDeals

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

CompanyDrug

CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China

CompanyDrug

Ocumension Therapeutics Completes First-Patient Enrollment of OT-202 Phase III Trial for Dry Eye Disease in China

CompanyDeals

Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform

Policy / Regulatory

China NPC Passes Medical Security Law, Establishing Multi‑Tier Medical Insurance Framework Effective 2027